Aqilion to Present Preclinical Data at Digestive Disease Week, May 2–5, Demonstrating That AQ280 Counteracts Dysfunctional Epithelial Barrier Function in Eosinophilic Esophagitis
Aqilion today announces that the company, in collaboration with Professor Arjan Bredenoord of Amsterdam University Medical Center and Dr Mirelle Kleuskens at University of Utrecht, will present new data from the AQ280 program at the scientific conference Digestive Disease Week (DDW) in Chicago. The study aims to advance understanding of how deterioration of esophageal barrier function can be managed in patients with Eosinophilic Esophagitis (EoE).
A poster entitled “THE HIGHLY SELECTIVE JAK1 INHIBITOR AQ280 COUNTERACTS INTERLEUKIN 13 AND ONCOSTATIN M-DRIVEN ESOPHAGEAL EPITHELIAL BARRIER DYSFUNCTION” will be presented on May 2 in the session “Eosinophilic Esophagitis: Biology and Mechanisms.” The study demonstrates effects that are unique to AQ280 compared with competing, already established treatments. AQ280 exhibits both anti-inflammatory properties and the ability to counteract the mechanisms that affect esophageal epithelial cells and lead to impaired barrier function.
Professor Arjan Bredenoord serves on Aqilion’s Scientific Advisory Board alongside Professor Evan Dellon and Dr. Luc Biedermann, with a focus on the company’s development of AQ280 – a selective JAK1 inhibitor as a novel treatment for EoE. All three advisory board members are well-recognized Key Opinion Leaders in EoE and are engaged in both the design of Aqilion’s clinical studies and the company’s research activities. The collaboration with the Scientific Advisory Board is notably aimed at generating new data for presentation at scientific conferences and in peer-reviewed publications.
Sarah Fredriksson, CEO of Aqilion, commented: “The new data being presented highlight unique properties of AQ280 in the context of EoE, providing the program with a strategically important competitive advantage over current treatment options. We are very pleased with the collaborations we have had the opportunity to conduct with our Scientific Advisory Board. We will continue to support studies of barrier function in EoE patients in collaboration with Professor Arjan Bredenoord and his colleagues, as we place great importance on contributing to a deeper understanding of the disease mechanisms. In doing so, Aqilion can contribute to a better future for patients.”
For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.co